Weight Loss Drug Tracker
- Following up on our our previous blog on anti-obesity drugs, Eli Lilly’s Zepbound continues to have lower awareness relative to other GLP-1s.
- Despite limited general awareness demand has already surpassed supply leading to nationwide shortages.
- Occam empowers users to evaluate key insights in the weight loss drug and broader pharmaceutical market, offering a unique, data-driven perspective into the industry.
- Become a subscriber today to access these real-time updates and critical contextual insights.
